MYC and cancer: In this context, the fluorquinolone derivative CX-3543 (quarfloxin), which has been the first-in-class G4 ligand to reach phase II clinical trials for cancer [57], has been demonstrated to affect MYC transcription indirectly, according to such a complex regulatory mechanism.